Eschenbach "not fit" to lead FDA: Wolfe

26 March 2006

Andrew von Eschenbach "is not qualified to lead the US Food and Drug Administrations," claims Sidney Wolfe, director of Public Citizen's Health Research Group. If confirmed by the US Senate as the next Commissioner, he "will become yet another Bush appointee whose main reason for being selected is that he is a family friend, someone who has been warmly embraced by the regulated industries - especially the pharmaceutical industry - and someone who has been and will continue to be loyal to the White House agenda," says Dr Wolfe.

"Dr von Eschenbach continues to exhibit extraordinarily bad judgment, a lack of being in touch with reality and insensitivity to the hopes and fears of other cancer patients and their friends and families, as evidenced by his oft-stated "plan" to eliminate the suffering and death from cancer by 2015. Eradicating cancer within 10 years is not realistic, and by making this statement, [Dr] von Eschenbach is cruelly raising people's hopes," says Dr Wolfe.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight